Squarepoint
STLN

Squarepoint’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Squarepoint’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2K Sell
23,831
-37,933
-61% -$116K ﹤0.01% 4111
2025
Q4 		$220K Sell
61,764
-80,790
-57% -$300K ﹤0.01% 3805
2025
Q3 		$498K Buy
+142,554
New +$488K ﹤0.01% 3238
2024
Q2 		– Sell
-105,824
Closed -$167K – 4653
2024
Q1 		$167K Buy
105,824
+8,962
+9% +$17K ﹤0.01% 3670
2023
Q4 		$198K Buy
+96,862
New +$168K ﹤0.01% 3600

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's STLN Position: Q1 2026 in Review

Squarepoint reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 61% in Q1 2026, selling an estimated $116K and leaving 23,831 shares worth $73.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4111.

Squarepoint first reported a position in STLN in Q4 2023 and has held it in 5 quarters since. The position peaked at $498K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Squarepoint held 23,831 shares of Starling Oncology Institute, Inc. Common Stock worth $73.2K as of Q1 2026.
  • Squarepoint sold 37,933 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $116K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4111 holding.
  • Squarepoint first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2023 and has held it in 5 quarters since.
  • Squarepoint's Starling Oncology Institute, Inc. Common Stock position peaked at $498K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.